Morgan Stanley Issues Pessimistic Forecast for Zimmer Biomet (NYSE:ZBH) Stock Price

Zimmer Biomet (NYSE:ZBH - Get Free Report) had its price target reduced by equities research analysts at Morgan Stanley from $115.00 to $95.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an "equal weight" rating on the medical equipment provider's stock. Morgan Stanley's price target would indicate a potential upside of 3.53% from the company's current price.

Several other equities analysts have also recently issued reports on ZBH. Robert W. Baird decreased their price target on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research report on Tuesday. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. JPMorgan Chase & Co. decreased their price target on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating for the company in a research note on Tuesday. Stifel Nicolaus set a $115.00 target price on Zimmer Biomet in a report on Tuesday. Finally, Raymond James lowered their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $118.15.

Zimmer Biomet Stock Performance

Shares of ZBH traded up $1.28 during midday trading on Tuesday, reaching $91.76. 1,530,588 shares of the stock were exchanged, compared to its average volume of 1,683,982. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The stock's 50 day simple moving average is $105.24 and its 200 day simple moving average is $106.42. Zimmer Biomet has a twelve month low of $89.92 and a twelve month high of $122.25. The company has a market cap of $18.15 billion, a P/E ratio of 20.66, a PEG ratio of 1.95 and a beta of 0.78.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. During the same quarter in the previous year, the firm posted $1.94 EPS. The business's revenue for the quarter was up 1.1% compared to the same quarter last year. On average, sell-side analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current year.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.95% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ZBH. B. Riley Wealth Advisors Inc. raised its holdings in shares of Zimmer Biomet by 17.5% in the third quarter. B. Riley Wealth Advisors Inc. now owns 2,404 shares of the medical equipment provider's stock valued at $260,000 after purchasing an additional 358 shares during the last quarter. GAMMA Investing LLC increased its stake in Zimmer Biomet by 67.6% in the 4th quarter. GAMMA Investing LLC now owns 2,298 shares of the medical equipment provider's stock valued at $243,000 after buying an additional 927 shares during the last quarter. Nordea Investment Management AB lifted its position in shares of Zimmer Biomet by 3.9% during the 4th quarter. Nordea Investment Management AB now owns 16,333 shares of the medical equipment provider's stock worth $1,732,000 after buying an additional 609 shares in the last quarter. First Hawaiian Bank boosted its stake in shares of Zimmer Biomet by 14.0% in the 4th quarter. First Hawaiian Bank now owns 20,400 shares of the medical equipment provider's stock worth $2,155,000 after buying an additional 2,500 shares during the last quarter. Finally, ORG Partners LLC grew its holdings in shares of Zimmer Biomet by 14,497.5% in the fourth quarter. ORG Partners LLC now owns 5,839 shares of the medical equipment provider's stock valued at $617,000 after acquiring an additional 5,799 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.